"Through wind and rain, ten years on, I feel that I and every Beike person are fortunate." On camera, Dr. Hu Xiang, polite and gracious, recounts his entrepreneurial story in front of the reporter. This July marks the 10th anniversary of Beike Biotech. Over the past decade, Beike has grown from an obscure small company into a representative enterprise in China's cell therapy field.
On August 8, the Shenzhen TV Finance Channel program High-End Interviews, in this episode "At the Frontier of Global Cell Therapy", sat down with Dr. Hu Xiang, a leading figure in China's stem cell and regenerative medicine industry and Chairman of Shenzhen Beike Biotechnology Co., Ltd. The episode explored the inspiring story of an entrepreneur who gave up favorable conditions abroad to return to China to start a business, dedicating himself to cutting-edge stem cell basic research as well as immune cell clinical application research and technology services, creating multiple "firsts" in the biomedical field. It captures the extraordinary character of an outstanding entrepreneur who, with a strong sense of responsibility and mission, strives tirelessly to keep Chinese biomedicine at the global forefront.
During the interview, Dr. Hu Xiang reviewed his entrepreneurial journey and shared the development of Beike Biotech — from seizing opportunities for innovation to successfully building the Beike Biotech brand, from advanced scientific research and technologies to clinical tools that solve patient problems, from cell therapy R&D to providing cell storage services and preparation technology services from various sources — giving viewers a deeper understanding of Beike Biotech and Dr. Hu himself. Dr. Hu said that Beike Biotech has grown into an important representative of Shenzhen's "innovation chain + industry chain" for cell therapy, participating in the construction and layout of the major infrastructure for precision medicine and personalized cell therapy — the "Shenzhen Comprehensive Cell Bank + Shenzhen Regional Cell Preparation Center".
On the very day of the High-End Interviews shoot, Xinhua News Agency had just reported on Beike's publication of a major outcome of the 12th Five-Year Plan National 863 Program — published in BMC Medicine, the multicenter, randomized, double-blind, placebo-controlled clinical study of umbilical cord mesenchymal stem cells in the treatment of acute myocardial infarction conducted over five years by Beike together with 11 cardiac centers including the PLA Navy General Hospital. The publication of these findings has, on real clinical evidence, also confirmed the correctness and scientific basis of the "Comprehensive Cell Bank + Regional Cell Preparation Center" cell therapy industry layout. As cell therapy technology continues to advance rapidly, clinical translation efficiency is improving, and the quality of public healthcare will be greatly enhanced.
High-End Interviews is a flagship business interview program of the Shenzhen TV Finance Channel. Its guests are renowned domestic and international entrepreneurs. The program focuses on current social hotspots, taking an economic-observation perspective to rationally examine financial topics and to share entrepreneurs' founding stories and business wisdom.
